1. Zhang, Hao, Zhu, Shuangli, Zhou, Haiting, Xia, Xiaohui, Xiong, Huihua. 2023. Identification of MTHFD2 as a prognostic biomarker and ferroptosis regulator in triple-negative breast cancer. In Frontiers in oncology, 13, 1098357. doi:10.3389/fonc.2023.1098357. https://pubmed.ncbi.nlm.nih.gov/36726381/
2. Shang, Man, Yang, Huijie, Yang, Ran, Yu, Qiujing, Wang, Ting. 2021. The folate cycle enzyme MTHFD2 induces cancer immune evasion through PD-L1 up-regulation. In Nature communications, 12, 1940. doi:10.1038/s41467-021-22173-5. https://pubmed.ncbi.nlm.nih.gov/33782411/
3. Chen, Qian, Huang, Peng, Song, Xin-Li, Zhang, Sen-Mao, Qin, Jia-Bi. . [Association of maternal MTHFD1 and MTHFD2 gene polymorphisms with congenital heart disease in offspring]. In Zhongguo dang dai er ke za zhi = Chinese journal of contemporary pediatrics, 24, 797-805. doi:10.7499/j.issn.1008-8830.2203002. https://pubmed.ncbi.nlm.nih.gov/35894196/
4. Morscher, Raphael J, Ducker, Gregory S, Li, Sophia Hsin-Jung, Sperl, Wolfgang, Rabinowitz, Joshua D. 2018. Mitochondrial translation requires folate-dependent tRNA methylation. In Nature, 554, 128-132. doi:10.1038/nature25460. https://pubmed.ncbi.nlm.nih.gov/29364879/
5. Huang, Jun, Qin, Yinyin, Lin, Canfeng, Huang, Xiaoguang, Zhang, Feiran. 2021. MTHFD2 facilitates breast cancer cell proliferation via the AKT signaling pathway. In Experimental and therapeutic medicine, 22, 703. doi:10.3892/etm.2021.10135. https://pubmed.ncbi.nlm.nih.gov/34007312/
6. Pardo-Lorente, Natalia, Gkanogiannis, Anestis, Cozzuto, Luca, Ponomarenko, Julia, Sdelci, Sara. 2024. Nuclear localization of MTHFD2 is required for correct mitosis progression. In Nature communications, 15, 9529. doi:10.1038/s41467-024-51847-z. https://pubmed.ncbi.nlm.nih.gov/39532843/
7. Gao, Yixing, Feng, Lan, Zhang, Luping, Geng, Jianhui, Zhang, Erlong. 2022. ATF4/MYC Regulates MTHFD2 to Promote NSCLC Progression by Mediating Redox Homeostasis. In Disease markers, 2022, 7527996. doi:10.1155/2022/7527996. https://pubmed.ncbi.nlm.nih.gov/36051358/
8. Achreja, Abhinav, Yu, Tao, Mittal, Anjali, Lu, Xiongbin, Nagrath, Deepak. 2022. Metabolic collateral lethal target identification reveals MTHFD2 paralogue dependency in ovarian cancer. In Nature metabolism, 4, 1119-1137. doi:10.1038/s42255-022-00636-3. https://pubmed.ncbi.nlm.nih.gov/36131208/
9. Shi, Xiaokai, Peng, Xiangrong, Chen, Yin, Zhang, Lifeng, Gao, Shenglin. 2023. Overexpression of MTHFD2 represents an inflamed tumor microenvironment and precisely predicts the molecular subtype and immunotherapy response of bladder cancer. In Frontiers in immunology, 14, 1326509. doi:10.3389/fimmu.2023.1326509. https://pubmed.ncbi.nlm.nih.gov/38130721/
10. Huang, Meihui, Xue, Jiajian, Chen, Zhiming, Du, Zepeng, Liu, Mingfa. 2022. MTHFD2 suppresses glioblastoma progression via the inhibition of ERK1/2 phosphorylation. In Biochemistry and cell biology = Biochimie et biologie cellulaire, 101, 112-124. doi:10.1139/bcb-2022-0291. https://pubmed.ncbi.nlm.nih.gov/36493392/